Present and future of tyrosine kinase inhibitors in renal cell carcinoma: Analysis of hematologic toxicity

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 2, 2012, Pages 104-110

  Santoni, Matteo ^a   Rizzo, Mimma ^b   Burattini, Luciano ^a   Farfariello, Valerio ^c   Berardi, Rossana ^a   Santoni, Giorgio ^c   Cartenì, Giacomo ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Hematologic toxicities; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; AXITINIB; CD135 ANTIGEN; CEDIRANIB; DOVITINIB; FLT3 LIGAND; INTERLEUKIN 2; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SARACATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB;

ANEMIA; ARTERIAL THROMBOEMBOLISM; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMATOPOIESIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MEGALOCYTOSIS; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; ONCOGENE C KIT; OVERALL SURVIVAL; POLYCYTHEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HEMATOPOIESIS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84863902306     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112801619719     Document Type: Review

References (69)

1. Karaman MW, Herrgard S, Treiber DK, Daniel KT, Paul G, Corey E, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127-32.
2. Kumar R, Crouthamel M-C, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101: 1717-23.
3. Pessina A, Albella B, Bueren J, Brantom P, Casati S, Gribaldo L, et al. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In vitro 2001; 6:729-40.
4. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237-45.
5. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182:18-32.
6. Rappold I, Ziegler BL, Köhler I, Marchetto S, Rosnet O, Birnbaum D, et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 1997; 90:111-25.
7. Adolfsson J, Borge OJ, Bryder D, Theilgaard-Mönch K, Astrand-Grundström I, Sitnicka E, et al. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 2001; 15: 659-69.
8. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003; 198: 305-13.
9. Matthews W, Jordan CT, Wiegand GW, Pardoll D, and Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-52.
10. Rosnet O, Marchetto S, deLapeyriere O, and Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991; 6: 1641-50.
11. Lyman SD and Jacobsen SE. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91:1101-34.
12. Wodnar-Filipowicz A. Flt3 Ligand: Role in Control of Hematopoietic and Immune Functions of the Bone Marrow. News Physiol Sci 2003; 18: 247-51.
13. Gunawardane, R.N. Phosphorilated fms-related tyrosine kinase 3 biomarker assay. US20110275094 (2011).
14. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008; 180: 7358-67.
15. Weldt, M.D., Ding, H., Thomas, S.A., Elmore, S.W., Shen, W., Dickman, D. A, Augeri, D. Biaryl carboxylic acid apoptosis promoters. US7989656 (2011).
16. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3:147-61.
17. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95:3489-97.
18. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortmanfiet K, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-62.
19. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, et al. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 1997; 159:2222-31.
20. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997; 179:174-84.
21. Ceredig R, Rauch M, Balciunaite G, Rolink AG. Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood 2006; 108:1216-22.
22. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996; 88: 2004-12.
23. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, Stadler WM. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: Clinical and biologic activity. J Immunother 2002; 25:269-77.
24. Lyman, S.D., Beckmann, P.M. Methods of using FLT3-ligand in the treatment of cancer. US20110053863 (2011).
25. Griffin, J.D., Manley, P.W. Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity. US7973031 (2011).
26. Li, Y., Lu, D., Surguladze, D., Tonra, J.R. Anti-FLT3 antibodies. US8071099 (2011).
27. Yasumoto, M., Shimada, M., Hino, F., Kato, I. Composition for inhibiting function of human flt3. US 20110105582 (2012).
28. Andre C, Hampe A, Lachaume P, Martin E, Wang XP, Manus V, et al. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. Genomics 1997; 39: 216-26.
29. Johan L, Shivakrupa R, Diana L. Synergistic Growth of Stem Cell Factor and Granulocyte Macrophage Colony-stimulating Factor Involves Kinase-dependent and-independent Contributions from c-Kit. J Biol Chem 2004; 279: 44544-53.
30. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988; 7:1003-11.
31. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-51.
32. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr Opin Cell Biol 1991; 3: 939-46.
33. Borge OJ, Adolfsson J, Martensson I, Jacobsen SEW. Lymphoidrestricted development from multipotent candidate murine stem cells: distinct and complementary functions of the c-kit and FLT3-ligands. Blood 1999; 94:3781-90.
34. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 2004; 121: 878-83.
35. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 2005; 36: 262-68.
36. Naoyuki A, Younghee L, Byung-S Y, Seiji F, Young-June K, Charlie M, et al. c-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood 2002; 99: 4413-21.
37. Voisset E, Lopez S, Chaix A, Vita M, George C, Dubreuil P, De Sepulveda P. FES kinase participates in KIT-ligand induced chemotaxis. Biochem Biophys Res Commun 2010; 393:174-78.
38. Yamamoto, Y., Watanabe, T., Okada, M., Tsuruoka, A. c-Kit kinase inhibitor. US7994159 (2011).
39. Ibrahim, P.N., Hurt, C., Zhang, C., Zhang, J. Compounds modulating c-kit activity. US7947708 (2011).
40. Ng, G., Shen, W. Humanized c-Kit Antibody. US20110223165 (2011).
41. Wilhelm SM, Carter C, Tang L, Wilkie D, Mcabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
42. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34.
43. Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 2007; 356:115-24.
44. Talebi TN, Stefanovic A, Merchan J, Lian E, Silva O. Sunitinibinduced microangiopathic hemolytic anemia with fatal outcome. Am J Ther 2010 [Epub ahead of print].
45. Choi MD, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat 2008; 40:211-13.
46. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18:1745-47.
47. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011; 17:5858-66.
48. Schallier D, Trullemans F, Fontaine C, Decoster L, De Greve J. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res 2010; 29:5225-28.
49. Choueiri TK, Schutz FAB, Je Y, Rosenberg BJ. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28:2280-85.
50. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. JCO 2010; 28:1061-68.
51. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative eff ectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378: 1931-39
52. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009; 27: 5032.
53. Angevin E, Grünwald V, Ravaud A, Castellano DE, Lin CC, Gschwend JE, et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011; 29: 4551.
54. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study. Eur J Cancer 2012; 48: 527-37.
55. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 2011; 47: 2706-14.
56. Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S, et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer. J Clin Oncol 2009; 27: 5033.
57. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-20.
58. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100:1111-19.
59. Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y, Shu Y, Xu Q. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2010; 135: 55-62.
60. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009; 183: 8286-94.
61. Young MRI, Newby M, Wepsic TH. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987; 47: 100-6.
62. Buessow SC, Paul RD, Lopez DM. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J Natl Cancer Inst 1984; 73: 249-55.
63. Seung L, Rowley D, Dubeym P, Schreiber H. Synergy between Tcell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 1995; 92: 6254-58.
64. Chen, S.-H., Zhoum, Z., Pan, P.-Y. In vitro generation of myeloid derived supressor cells. US20120082688 (2012).
65. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kuniyasu Y%22%5BAuthor%5DA decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991-8.
66. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57.
67. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-44.
68. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12.
69. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, et al. Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003;101: 4457-63.